One of the questions that arises for people with well-controlled asthma is whether it’s better or worse for them to stop taking their long-acting beta2-agonist inhaler. Kayleigh Kew and Rebecca Normansell from the Cochrane Airways Group in London UK are part of the team that have tried to answer this in a new review in June 2015. They explain more in this podcast, starting with Rebecca and some background.